PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
/PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with...
Brandon Capital Medical Research Commercialisation Fund About Polyactiva Brandon Capital Medical Research Commercialisation Fund Health Care Amp Hospitals Biotechnology
Source: prnewswire.com